Sartorius AG (0NIQ) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Sartorius and Sartorius Steadim Biotech Conference Call and Live Webcast on H1 2020 six. I'm Moritz, your Chorus Call operator. I would like to remind you that all The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Petra Muller, Head of Investor Relations of Sartorius. Please go ahead. Thank you, and hello, and a warm welcome from my side. So today, I'm joined by our CEO, Michele Grosser by Florian Funk, our CFO by Rene Farber, Head of our Bioprocessing Division and CEO of Sartorius Stedim Biotech and also by Alexandra Gatzemaier, Head of our Lab Products and Services Division. As always, we will start with prepared remarks followed by the Q and A session. The call is scheduled to last one hour. As usual, please limit your questions to one, so that as many of you as possible can take part. In case we have some time at the end, we are of course happy to take on follow on questions. I'd like to point out that management comments during this call will include forward looking statements that involve risks and uncertainties. For discussion of risk factors, I encourage you to review the Safe Harbor statement contained in today's press release and the presentation. And with that, I'm pleased to hand over to our CEO, Michael Kors. Michael, please go ahead. Thank you, Petra, and a very warm welcome from my side as well. When I look back at the first half year, I'd say it's been an encouraging six months for Sartorius during which we continued our profitable growth trajectory. We delivered solid top line growth. We've improved profitability and we've generated strong cash flow. Before turning to the H1 business performance, let me share one personal observation. Over the past few...